These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 2698437

  • 1. [Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin].
    Pilheu JA, Galati MR, Yunis AS, De Salvo MC, Negroni R, García Fernández JC, Mingolla L, Rubio MC, Masana M, Acevedo C.
    Medicina (B Aires); 1989; 49(1):43-7. PubMed ID: 2698437
    [Abstract] [Full Text] [Related]

  • 2. Single dose kinetics of rifampicin and isoniazid in well-nourished and malnourished patients of tuberculosis.
    Garg SK, Dhand R, Malik SK, Kalra S, Gupta PH, Jha VK, Shukla VK, Lal R.
    Int J Clin Pharmacol Ther Toxicol; 1988 Aug; 26(8):417-20. PubMed ID: 3220617
    [Abstract] [Full Text] [Related]

  • 3. Interaction of ketoconazole with rifampin and isoniazid.
    Engelhard D, Stutman HR, Marks MI.
    N Engl J Med; 1984 Dec 27; 311(26):1681-3. PubMed ID: 6095080
    [No Abstract] [Full Text] [Related]

  • 4. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R.
    Int J Pharm; 2004 May 19; 276(1-2):41-9. PubMed ID: 15113612
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E, Azuaje C, Lopez RM, Domingo P, Curran A, Feijoo M, Pou L, Sánchez P, Sambeat MA, Colomer J, Lopez-Colomes JL, Crespo M, Falcó V, Ocaña I, Pahissa A.
    J Antimicrob Chemother; 2007 Apr 19; 59(4):690-7. PubMed ID: 17307771
    [Abstract] [Full Text] [Related]

  • 6. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
    Zwolska Z, Niemirowska-Mikulska H, Augustynowicz-Kopec E, Walkiewicz R, Stambrowska H, Safianowska A, Grubek-Jaworska H.
    Int J Tuberc Lung Dis; 1998 Oct 19; 2(10):824-30. PubMed ID: 9783530
    [Abstract] [Full Text] [Related]

  • 7. Serum concentrations of rifampicin and isoniazid in tuberculosis.
    Seth V, Beotra A, Seth SD, Semwal OP, Kabra S, Jain Y, Mukhopadhya S.
    Indian Pediatr; 1993 Sep 19; 30(9):1091-8. PubMed ID: 8125594
    [Abstract] [Full Text] [Related]

  • 8. Correlation between steady-state plasma concentration of antituberculous drugs and age, inclusion of rifampicin in the treatment regimen, adverse drug reactions and other clinical parameters.
    Woo J, Chan C, Chan R, Cheung W, Or K, Chan K.
    J Med; 1995 Sep 19; 26(5-6):279-94. PubMed ID: 8721904
    [Abstract] [Full Text] [Related]

  • 9. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.
    Nijland HM, Ruslami R, Suroto AJ, Burger DM, Alisjahbana B, van Crevel R, Aarnoutse RE.
    Clin Infect Dis; 2007 Oct 15; 45(8):1001-7. PubMed ID: 17879915
    [Abstract] [Full Text] [Related]

  • 10. [Plasma levels of rifampicin and isoniazid and serum levels of aminotransferases in combined tuberculostatic treatment (author's transl)].
    Knop P, Kindler U, Austerhoff A.
    Dtsch Med Wochenschr; 1977 Dec 30; 102(52):1913-5. PubMed ID: 598300
    [Abstract] [Full Text] [Related]

  • 11. [Antibacterian activity modifications of serum isoniazid when using it with rifampicin (author's transl)].
    Nouhouayi A, Bergogne-Berezin E, Lafaix C.
    Pathol Biol (Paris); 1982 Jun 30; 30(6):389-93. PubMed ID: 7050848
    [Abstract] [Full Text] [Related]

  • 12. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H.
    Kekkaku; 2003 Oct 30; 78(10):611-7. PubMed ID: 14621568
    [Abstract] [Full Text] [Related]

  • 13. Tuberculosis treated with rifampicin, ethambutol and isoniazid: Danish tuberculosis trial 1972-1974.
    Engbaek HC, Heckscher T, Højgaard C, Larsen SO, Rasmussen KN, Vergmann B.
    Eur J Respir Dis; 1982 Mar 30; 63(2):84-93. PubMed ID: 7040100
    [Abstract] [Full Text] [Related]

  • 14. Effects of rifampicin with and without isoniazid in rheumatoid arthritis.
    McConkey B, Situnayake RD.
    J Rheumatol; 1988 Jan 30; 15(1):46-50. PubMed ID: 3351840
    [Abstract] [Full Text] [Related]

  • 15. Bioequivalence study of rifampicin in fixed-dose combination of rifampicin and isoniazid vs. separate formulations.
    Panchagnula R, Singh I, Kaur KJ, Kaul CL.
    Methods Find Exp Clin Pharmacol; 1999 Nov 30; 21(9):625-8. PubMed ID: 10669909
    [Abstract] [Full Text] [Related]

  • 16. The pharmacokinetic factors and bioavailability of rifampicin, isoniazid and pyrazinamid fixed in one dose capsule.
    Zwolska Z, Augustynowicz-Kopeć E, Niemirowska-Mikulska H.
    Acta Pol Pharm; 2002 Nov 30; 59(6):448-52. PubMed ID: 12669769
    [Abstract] [Full Text] [Related]

  • 17. [Adjusting or not adjusting isoniazid dosage?].
    Parrot R, Boval C, Grosset J, Gaillard JP.
    Rev Fr Mal Respir; 1983 Nov 30; 11(5):705-12. PubMed ID: 6658156
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Serum concentration of isoniazid following administration of the drug alone and in combination with rifampicin in patients of pulmonary tuberculosis.
    Singhal KC, Rathi R, Kishore K, Varshney SC, Varshney DP.
    Indian J Physiol Pharmacol; 1986 Nov 30; 30(1):115-7. PubMed ID: 3818028
    [No Abstract] [Full Text] [Related]

  • 20. Isoniazid and acetylisoniazid kinetics in serum and urine in pulmonary primary complex with intermittent regimen.
    Seth V, Seth SD, Beotra A, Semwal OP, D'monty V, Mukhopadhya S.
    Indian Pediatr; 1994 Mar 30; 31(3):279-85. PubMed ID: 7896362
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.